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ABSTRACT
STEAP1 gene is overexpressed in several kinds of tumors, particularly in prostate 
cancer. Besides STEAP1, there is another related gene, STEAP1B, which may encode 
two different transcripts. Although several studies have been pointing STEAP1 as a 
putative immunotherapeutic target and biomarker, the mechanisms underlying its 
regulation are not fully understood. In silico analysis allowed us to show that STEAP1 
and STEAP1B share high homology, but with slight differences at structural level. 
Experiments with prostate cells showed that STEAP1B2 is overexpressed in cancer 
cells. Regarding STEAP1 regulation, it is demonstrated that the stability of mRNA and 
protein is higher in LNCaP than in PNT1A cells. Of note, serum triggered opposite 
effects in LNCaP and PNT1A in relation to STEAP1 stability, e.g., increasing it in PNT1A 
and decreasing in LNCaP. These results suggest that STEAP1 may be regulated by 
post-transcriptional and post-translational modifications (PTM), which may differ 
between non-neoplastic and neoplastic cells. These PTM are supported through in 
silico analysis, where several modifications such as N-glycosylation, N-Glycation, 
Phosphorylation and O-linked β-N-acetylglucosamine, may occur in STEAP1 protein. 
In conclusion, these data indicate that STEAP1B2 is overexpressed in neoplastic cells, 
and PTM may be involved in regulation of STEAP1 expression in prostate cells.
INTRODUCTION
The six transmembrane epithelial antigen of the 
prostate 1 (STEAP1) is overexpressed in prostate cancer, 
and other malignant tumors with slightly less intensity 
[1-4]. Regarding normal tissues, STEAP1 expression is 
almost restricted to prostatic cells preferentially located 
on the plasma membrane of epithelial cells, particularly 
on cell-cell junctions, and to a lesser extend dispersed 
on the cytoplasm [2, 3, 5]. Although its precise cellular 
function is still not fully understood, STEAP1 appears 
to function as a transporter or ion channel, taking part 
on inter- and intracellular communication, possibly 
regulating cell proliferation and invasiveness [1-3, 6]. 
Several studies have been pointed out the STEAP1 as a 
potential immunotherapeutic target as well as a biomarker, 
emphasizing its clinical relevance [7-11]. Besides STEAP1 
gene, another related gene, STEAP1B, is encoded by the 
human genome. This gene is located at a different arm 
of the same chromosome as STEAP1, and may originate 
two different transcripts, STEAP1B1 and STEAP1B2. 
However, its expression in prostate cells is unstudied. 
Recently, our research group has demonstrated that 
STEAP1 is regulated by androgens and estrogens on the 
LNCaP cell line [5]. However, the mechanisms underlying 
STEAP1 over-expression on prostate cancer remain to be 
elucidated. It is well known that the regulation of gene 
expression could occur not only at transcription level 
but also at post-transcriptional and post-translational 
levels. In fact, events like cell-cycle progression, signal 
transduction and apoptosis, which are closely associated 
with oncogenesis, are influenced by mRNA stability as 
well as the rate of protein degradation [12-17]. It has been 
reported that tumors may activate endogenous mechanisms 
to increase mRNA stability of genes encoding oncogenes, 
cytokines, growth factors, and enzymes, leading to an 
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enhanced protein over-expression, consequently raising 
cell growth and inflammatory processes known to be 
involved in the onset and progression of carcinogenesis 
[18-23]. Post-translational modifications (PTM) are 
intrinsically involved on regulating protein function, 
and therefore, are crucial for a variety of cellular 
processes, such as transcription, replication, cell cycle, 
apoptosis and cell signaling [24, 25]. Overall, we aimed 
to conduct an extensive in silico analysis of STEAP1 
and STEAP1B, and to evaluate STEAP1 and STEAP1B 
expression in human prostate cell lines. In addition, the 
putative post-transcriptional and PTM modifications are 
evaluated through STEAP1 mRNA and protein stability, 
supplemented by a post-translational in silico analysis.
RESULTS
STEAP1 and STEAP1B gene share high homology 
and are differentially expressed in human prostate 
cell lines
A detailed in silico analysis allowed to compare 
the genomic organization of STEAP1 and STEAP1B 
genes. STEAP1 gene is found close to the telomeric 
region on chromosome 7q21.13, encoding a transcript 
with 1.3 Kb, which originates a 339 aa mature protein 
(39.72KDa), with six predicted transmembranar regions, 
connected by three extracellular and two intracellular 
loops, and both COOH and NH2 intracellular terminal. 
The transmembrane domains are thought to be located 
between 73-95, 117-139, 164-182, 218-240, 252-274, 
289-311 of the aa sequence (www.ncbi.nlm.nih.gov/
protein/NP_036581.1; http://www.cbs.dtu.dk/services/
TMHMM/) . STEAP1B gene is localized on chromosome 
7p15.3 and may originate two different transcripts, namely 
STEAP1B1 and STEAP1B2 (Figure 1). In comparison to 
the STEAP1 gene, STEAP1B1 has an additional exon, 
and a very large intron 4, with 53809bp on STEAP1B1 
and 72728bp on STEAP1B2. STEAP1B1 is the longer 
transcript spanning approximately 1.3 Kb, and may 
encode the longer isoform with 342 aa (39.547KDa), 
containing four potential transmembranar regions 
between aa 117-139, 163-182, 218-240 and 250-267, 
two intracellular and two extracellular loops, and COOH 
and NH2 intracellular terminal regions (www.ncbi.nlm.
nih.gov/protein/NP_001157932.1; http://www.cbs.
dtu.dk/services/TMHMM/). STEAP1B2 transcript has 
approximately 1.2Kb, and may encode a protein with 245 
aa (28.684 KDa) with three potential transmembranar 
regions situated between aa 98-120, 144-163 and 199-
221, one intracellular and one extracellular loops, an 
intracellular NH2 termini and an extracellular COOH 
region (www.ncbi.nlm.nih.gov/protein/NP_997225.1; 
http://www.cbs.dtu.dk/services/TMHMM/) (Figure 1). 
STEAP1B2 uses an alternate in-frame splice site in the 
5’ coding region and an alternate 3’ exon with a distinct 
3’ coding region and 3’ UTR, compared to variant 1. 
The resulting isoform lacks an internal segment near the 
N-terminus and has a shorter and distinct C-terminus when 
compared to isoform 1 (http://www.ncbi.nlm.nih.gov/
gene?term=STEAP1B). . This detailed analysis reveals 
that STEAP1 and STEAP1B1 isoforms share 89% and 
STEAP1 and STEAP1B2 91% of homology (http://blast.
ncbi.nlm.nih.gov/Blast.cgi).
STEAP1, STEAP1B1 and STEAP1B2 mRNA are 
differentially expressed in prostate cells lines. On the non-
neoplastic prostate cells, PNT1A and PNT2, STEAP1, 
STEAP1B1 and STEAP1B2 mRNAs have little to no 
expression. On the other hand, on the malignant prostate 
cells, LNCaP and PC3, STEAP1 and STEAP1B2 are 
highly expressed, particularly STEAP1 (Figure 2A). 
STEAP1B1 mRNA is mainly expressed on PNT2 and 
PC3 cells, and under-expressed on LNCaP cells. The 
expression of STEAP1 protein was evaluated by western 
blot analysis (Figure 2B). Two immunoreactive bands 
could be identified, one of 30 KDa on PNT1A and other of 
36 KDa on LNCaP cells. As seen in Figure 2B, STEAP1 
protein is highly expressed on LNCaP cells, followed by 
PNT1A, PC3 and PNT2 with no expression.
Stability of STEAP1 mRNA and protein in human 
prostate cell lines
To evaluate the hypothesis that post-transcriptional 
and PTM mechanisms could be involved in the differential 
expression of STEAP1 between non-neoplastic and 
neoplastic cells, PNT1A and LNCaP cells were chosen to 
determine STEAP1 mRNA and protein stability through 
qPCR and western blot analysis, respectively. Cells were 
primarily cultured on CM, and STEAP1 mRNA stability 
was established by assessing the relative decay rates of 
STEAP1 after Act D treatment at 0, 1, 2, 4, 8 and 12h 
(Figure 3A). STEAP1 protein stability was determined 
after inhibiting protein synthesis with Chx for 0, 1, 2, 4, 6, 
8 and 16h (Figure 3B). On PNT1A cells, the approximate 
half-life of STEAP1 mRNA levels is 4h, whereas on 
LNCaP is about 10h. Comparing the decaying mRNA 
levels of both cell lines, it is noticed that STEAP1 mRNA 
is more stable on LNCaP cells than on PNT1A cells. 
Regarding to STEAP1 protein expression after exposure 
to Chx, the approximate half-life of STEAP1 protein on 
PNT1A cells is about 6h, whereas the levels on LNCaP 
are still high even after 16h of treatment with Chx. In 
accordance to the mRNA data, it is clear that STEAP1 
protein is also more stable on LNCaP than on PNT1A 
cells. However, no relationship seems to occur between 
the decay rates of mRNA and protein, namely on LNCaP 
cells.
It is well known that FBS (serum) contains hormones 
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Figure 1: In silico analysis of human STEAP1 and STEAP1B gene. Genomic organization (A) and transcripts (B) resulting from 
STEAP1 and STEAP1B gene. Exons (E), Introns (I) and their molecular sizes in bp (base pairs) are indicated. The sequence ATG and TAG/
TAA corresponds to initiation and STOP codons, respectively. White boxes indicate non-coding exons, and black or grey boxes represent 
regions of coding exons depending on transcript encoded by STEAP1B gene. C- Alignment of amino acids sequences of STEAP1 and 
putative STEAP1B isoforms. The underlined amino acids sequences correspond to predicted transmembrane regions. * indicate identical 
amino acids among STEAP1s proteins; “:” indicate different amino acids but with similar physical-chemistry properties. D- Prediction of 
transmembrane helices in STEAP1, STEAP1B1 and STEAP1B2 proteins. All sequences were retrieved from http://genome.ucsc.edu/ and 
the alignment was carried out using Clustal Omega (https://www.ebi.ac.uk/Tools/msa/clustalo/). The prediction of transmembrane helices 
was performed resorting to Center for Biological Sequence analysis (http://www.cbs.dtu.dk/services/TMHMM/).
Figure 2: Differential expression of STEAP1, STEAP1B1 and STEAP1B2 on prostate cell lines. A. mRNA expression of 
STEAP1 and its isoforms were determined by qPCR. B. STEAP1 protein expression was determined by Western blot. mRNA and protein 
expression was normalized with hGAPDH and β-actin, respectively. Error bars indicate mean ± SEM of n=6. *p<0.05, ***p<0.001 (One-
way ANOVA followed by Bonferroni test) compared with PNT1A expression.
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and growth factors important to cell homeostasis. 
Therefore, the effect of serum on STEAP1 mRNA and 
protein stability was investigated. In the presence of FBS, 
STEAP1 mRNA expression increased 2 fold after 8h of 
stimuli on PNT1A cells (Figure 4A, upper left), whereas 
on LNCaP cells STEAP1 mRNA expression decreased 
almost 2 fold after 12h of stimuli with FBS (Figure 4B, 
lower left). The effect of FBS in STEAP1 protein levels at 
these time points was in accordance to STEAP1 mRNA, 
i.e., increased at 8h on PNT1A (Figure 4A right upper) 
and decrease after 12h on LNCaP cells (Figure 4B, lower 
right). These results show a clear opposite response to 
hormones and growth factors, which are present in FBS, 
in non-neoplastic and neoplastic prostate cell lines. 
In silico analysis of post-translational 
modifications in STEAP1 protein 
In an attempt to uncover the causes behind the above 
mentioned differences on STEAP1 protein stability, a 
closer insight into PTM was achieved through an extensive 
in silico analysis. Alterations such as N-glycosylation, 
glycation, phosphorylation sites and O-β-GlcNAc anchor 
sites on STEAP1 aa sequences were investigated. As seen 
on Figure 5A, two N-X-S/T consensus sequences [32] 
were found on STEAP1 sequence, but a single potential 
N-glycosylation site was identified at position 143, 
corresponding to the asparagine aa. Although another 
asparagine was signaled, the potential score was below the 
threshold line. Potential glycation sites occur in several 
lysines (9/24) of STEAP1 protein. These potentially 
glycated aa are located at positions 5, 15, 17, 30, 108, 
148, 149, 156 and 162 (Figure 5B). It is well known 
that three distinct aa (serine, threonine and tyrosine) 
have the ability to be phosphorylated. According to the 
results retrieved from NetPhos 2.0 Server, four serines 
(positions 3, 187, 240 and 244), two threonines (positions 
160 and 246) and four tyrosines (positions 27, 147, 219 
and 252) are potentially phosphorylated on STEAP1 
(Figure 5C). Several kinase enzymes with the potential to 
Figure 3: STEAP1 mRNA and protein stability in human prostate cell lines. Comparison between PNT1A and LNCaP 
STEAP1 mRNA (A) and protein (B) stability in complete culture medium. mRNA and protein expressions were determined by qPCR and 
Western blot, respectively. mRNA and protein expression was normalized with hGAPDH and β-actin, respectively. Error bars indicate 
mean ± SEM of n=6. *p<0.05, p**<0.01 (t-test) comparing PNT1A and LNCaP STEAP1 expression at each indicated time.
Figure 4: Effect of serum on PNT1A (A- upper left and right) and LNCaP (B- lower left and right) STEAP1 mRNA and 
protein stability, after treatment with Act D and Chx, respectively. mRNA and protein fold variation relatively to incomplete 
medium (IM) were determined by qPCR and Western blot, respectively. mRNA and protein expression was normalized with hGAPDH and 
with β-actin, respectively. Error bars indicate mean ± SEM of n=6. *p<0.05, **p<0.01 (t- test) comparing (IM) and complete medium (CM) 
STEAP1 expression at each indicated time.
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phosphorylate different aa on STEAP1 sequence were also 
identified. As seen on Table 2, the threonine at position 
160 presents the highest score to be phosphorylated by 
protein kinase C. GlcNAcylation usually occurs in parallel 
with phosphorylation, and the two are frequently mutually 
exclusive [33, 34]. In fact, the potential O-β-GlcNAc 
anchor sites can be found on threonines 236 and 333, as 
well as on serines 237 and 242 of the STEAP1 aa sequence 
(Figure 5D). 
DISCUSSION
STEAP1 is mainly expressed in normal and 
malignant prostate and the pursuit for understanding how 
its expression is regulated and modulated by internal and 
external factors is fundamental. Recently, Grunewald 
and colleagues described the existence of a STEAP1 
homolog gene, named STEAP1B [35]. STEAP1 and 
STEAP1B genes are located on chromosome 7, but on 
different arms, i.e., STEAP1 gene is located at the long 
arm (7q21.13) and STEAP1B on the short arm (7p15.3). 
Considering the high homology between STEAP1 and 
STEAP1B genes, it is possible that gene duplication may 
have occurred during genome evolution. STEAP1B gene 
gives rise to two transcripts, STEAP1B1 and STEAP1B2, 
which share several similarities to STEAP1, but may 
encode two different mature proteins of 332 aa and 245 
aa, respectively. Although the expression of STEAP1B 
at protein level still needs to be verified, these putative 
proteins also display transmembrane regions like STEAP1, 
but in a smaller number, suggesting that different roles 
could be played by these isoforms in comparison to 
STEAP1 protein. There are some common features present 
on the structure of STEAP family of proteins, such as the 
presence of an N-terminal with homology to the archaeal 
and bacterial F420H2:NADP
+ oxidoreductase (FNO)–
binding proteins and human NADPH-oxidoreductases, 
two conserved histidines that bind an intramembranar 
heme group known as the ACRATA domain, the presence 
of the Rossman fold within the N-terminal and the 
strikingly similarity between the C-terminal domain to 
the yeast FRE cytochrome b metalloreductase domain, 
indicating their possible role as oxidoreductases [36-39]. 
Both STEAP1B isoforms, lack the FNO-like domain, the 
Rossman fold and the NADPH-oxidoreductase domain, as 
STEAP1 [35, 36]. In addition, STEAP1B2 appears to be 
Figure 5: Prediction of N-glycosylation, glycation, phosphorylation and O-β-GlcNAc sites of STEAP1 using: A. 
NetNGlyc 1.0, B- NetGlycate 1.0, C. NetPhos 2.0 and D- YinOyang 1.2, respectively.
Table 1: Sequences, amplicons sizes and annealing temperatures for the different STEAP1 mRNA and the 
internal controls used for quantitative Real-Time PCR.
Oligo name Sequence (5´-3´) Amplicon Size (bp) Anneling temperature
hSTEAP1_619fw GGC GAT CCT ACA GAT ACA AGT TGC 128
60ºC
hSTEAP1_747rv CCA ATC CCA CAA TTC CCA GAG AC
hSTEAP1B1fw CTGGAAGCCTGGTAGCTTTG 162hSTEAP1B1rv GGCTGGCTGCTGATAAAATG 
hSTEAP1B2fw CGATTATTTGCAAACAGCCC 173hSTEAP1B2rv GGGAAGTTGCTAAAGGGTGA 
hGAPDH_74fw CGC CCG CAG CCG ACA CAT C 75hGAPDH_149rv CGC CCA ATA CAA TCC G 
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also missing the heme-binding sites, making it unfit to act 
as a ferric oxidoreductase [35].
STEAP1 mRNA overexpression is well described 
on LNCaP and PC3 cells [2]. We demonstrated that 
STEAP1B1 and STEAP1B2 mRNAs are also expressed on 
prostate cell lines. Alike in STEAP1, STEAP1B2 mRNA 
is also overexpressed in neoplastic cells when compared to 
non-neoplastic cells, suggesting that also STEAP1B2 may 
be dysregulated in cancer and demonstrating its potential 
application as a biomarker. STEAP1B1 mRNA can only 
be found in diminished levels on PNT2 and PC3 cells, and 
little or no expression on the LNCaP and PNT1A cells. 
These results seem to suggest that STEAP1B1 mRNA is 
not differentially expressed between normal and prostate 
cancer. However, it is needed to carry out studies using 
human prostate cancer cases to evaluate the expression 
profile of STEAP1B1 and STEAP1B2, as well as to clarify 
their clinical significance. 
A strong immunoreactive band of approximately 
36 KDa was detected on LNCaP cells, which must 
correspond to STEAP1 protein, as described by others [1, 
2, 6]. Interestingly, an immunoreactive band of 30 KDa 
was obtained on PNT1A cells. The different molecular 
weight of STEAP1 between LNCaP and PNT1A may 
result from different PTM on protein, as suggested by 
our results and discussed below. It is also possible that 
the immunoreactive band of 30 KDa may correspond 
to STEAP1B2, because this is the predicted molecular 
weight of STEAP1B2 isoform. Nonetheless, further 
analysis using specific antibodies against STEAP1B1 and 
STEAP1B2 are required to determine their expression.
Numerous studies have described that STEAP1 
is overexpressed in several kinds of tumors, but the 
mechanisms underlying its overexpression remain 
to be clarified. With this work we also attempted to 
unveil if STEAP1 expression would be regulated by 
post-transcriptional and PTM. Considering that both 
mRNA and protein stability display an important role at 
cellular level, in regulation of gene induction/expression, 
proliferation, cell signaling and apoptosis [12-16, 40], the 
STEAP1 stability in non-neoplastic and neoplastic prostate 
cell lines was evaluated. mRNA half-life and turnover are 
dependent on development stage or environmental factors, 
such cytokines, hormones, among others, decreasing its 
rate of transcription [40, 41]. The regulation of mRNA 
stability is intrinsically associated to the regulation of 
protein production [40]. The most stable mRNA and 
proteins are usually associated with vital processes such as 
translation, metabolic pathways and respiratory machinery 
[42]. According to the collected data, STEAP1 mRNA and 
protein are less stable in the PNT1A cells in comparison 
to the highly stable STEAP1 mRNA and protein on 
LNCaP cells. The enhancement of STEAP1 stability in 
LNCaP cells suggests that post-transcriptional and PTM 
may differ between non-neoplastic and neoplastic cells, 
contributing for STEAP1 overexpression in cancer cells. 
The evaluation of the effect of serum on STEAP1 stability 
shows that serum has opposite effects on STEAP1 stability, 
increasing it on PNT1A and decreasing on LNCaP cells. 
Recently, our research group demonstrated that treatment 
with serum or DHT down-regulates STEAP1 expression 
through androgen receptor (AR) [5]. Considering that 
DHT increases AR mRNA stability and consequently the 
levels of AR protein, it is liable to speculate that DHT 
present on serum may contribute to decreased STEAP1 
stability [43]. However, other factors may be involved in 
stability of STEAP1. 
The opposite effect of serum in STEAP1 stability on 
PNT1A cells reinforce that the mechanisms involved in 
regulation of STEAP1 may differ between non-neoplastic 
and neoplastic cells. Furthermore, the increased stability of 
both mRNA and protein on LNCaP cells is in accordance 
that stable mRNAs allow a wider translational timeframe 
for genes that are expressed at high levels [44]. 
There are several factors that could control mRNA 
Table 2: Putative Kinases enzymes involved on 
STEAP1 phosphorylation. Prediction was performed 
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and protein turnover on cells, and in an attempt to 
determine possible PTM’s in STEAP1 protein, in silico 
analysis was carried out. Four different types of PTM’s 
were found to be likely to occur in STEAP1 protein, 
namely N-glycosylation, glycation, phosphorylation 
and O-β-GlcNAcylation. STEAP1 protein is therefore 
potentially subjected to multisite modification, a 
phenomenon that modulates protein function by “loss-of-
function” and/or “gain-of-function” mechanisms as a result 
of interaction between the different modifications [25]. It is 
well documented that these types of modifications tend to 
confer higher stability to proteins and are often implicated 
on the etiology and pathogenesis of several diseases, 
including cancer [25, 45-50]. Furthermore, certain PTM’s 
may even be used as diagnostic targets and are known 
to enhance tumor cell proliferation and invasion, as in 
prostate cancer [51-53]. Further analysis is required to 
ascertain if these particular PTM’s are occurring on cells, 
and if they occur, it is crucial to evaluate the role of these 
modifications in carcinogenesis. 
In conclusion, STEAP1B transcripts have similar 
structural features to STEAP1, but may encode proteins 
with less transmembrane domains. STEAP1B2 transcript 
is also overexpressed on neoplastic prostate, making it 
worth to evaluate its potential as cancer biomarker. For 
the first time, we demonstrated that STEAP1 expression 
and regulation could also be under the control of several 
PTM. Clarifying the regulation of STEAP1 as well as the 
expression and function of STEAP1B on cells may open 
novel strategies for diagnosis and treatment of prostate 
cancer. 
MATERIAL AND METHODS
Cell culture and treatment
Human prostate cell lines (PNT1A, PNT2, LNCaP 
and PC3) were purchased from the European Collection 
of Cell Cultures (ECACC, Salisbury, UK). All cell lines 
were grown in RPMI 1640 medium (Gibco, Paisley, 
Scotland) supplemented with 10% FBS (Biochrom 
AG, Berlin, Germany) and 1% penicillin/streptomycin 
(Invitrogen, NY, USA), in a humidified chamber at 37ºC 
and a 5% CO2 atmosphere. Determination of STEAP1, 
STEAP1B1 and STEAP1B2 expression was determined 
through the collection of cells from three different 
passages. Evaluation of mRNA and protein stability was 
achieved with treatment with inhibitors of transcription 
[actinomycin D (Act D)], and translation [cycloheximide 
(Chx)], respectively. Two different approaches were 
carried out in order to evaluate STEAP1 mRNA and 
protein stability in cells: a) LNCaP and PNT1A cells were 
grown up to 60% confluence in Complete Medium [(CM) 
RPMI 1640, 10% FBS and1% penicillin/streptomycin]. 
This medium was then replaced by CM supplemented 
with Act D 1µg/mL, or Chx 1µg/mL. Cells were harvested 
after 0h, 1h, 2h, 4h, 8h and 12h to assess mRNA stability, 
and after 0h, 1h, 2h, 4h, 8h and 16h for protein stability; 
b) LNCaP and PNT1A cells were grown up to 60% in 
Incomplete Medium [(IM) without serum]. This medium 
was posteriorly supplanted by CM or IM supplemented 
with Act D 1µg/mL, or Chx 1µg/mL. Cells were harvested 
after 0h, 4h, 8h and 12h for mRNA stability, and after 8h 
and 12h for protein stability in PNT1A and LNCaP cells, 
respectively.
Total RNA extraction and cDNA synthesis
Total RNA from human prostate cell lines was 
obtained using TRI reagent (Ambion, UK) according to 
the manufacturer’s instructions. Total RNA integrity and 
quantification were assessed by agarose gel electrophoresis 
and measuring 260 and 280ηm absorvances on a 
nanospectrometer (Pharmacia Biotech, Ultraspec 3000). 
cDNA synthesis was carried out using NZY First-
Strand cDNA Synthesis Kit (Nzytech, Lisboa, Portugal) 
according to protocol. 
Total Protein Extraction
PNT1A, PNT2, LNCaP and PC3 cells were lysed on 
an appropriated volume of RIPA buffer (150 mM NaCl, 
1% Nonidet-P40 substitute, 0.5% Na-deoxycholate, 0.1% 
SDS, 50 mM Tris, 1 mM EDTA) supplemented with 1% 
protease cocktail and 10% PMSF. The total protein extract 
(supernatant) was obtained after centrifugation the cell 
lysate for 20min at 12000 rpm and 4ºC. Quantification of 
the total protein bulk was measured using the Bradford 
method (Biorad, CA, USA).
Quantitative Real-Time PCR analysis 
Quantitative real-time PCR (qPCR) was used to 
determine the expression of STEAP1, STEAP1B1 and 
STEAP1B2 in prostate cell lines and to establish PNT1A 
and LNCaP half-life of STEAP1 mRNA. qPCR reactions 
were performed on IQ5 Multicolor qPCR Detection 
System (Bio-Rad, Hercules, USA) using MaximaTM 
SYBR Green/Fluorescein qPCR Master Mix (Thermo 
Scientific, Vilnius, Lithuania). The efficiency of qPCR 
was determined for all designated primers (Table 1) with 
serial dilutions (1:1; 1:10; 1:100; 1:1,000) of the cDNA. 
qPCR reactions were performed using 1µl of cDNA in a 
20µl reaction containing 10µl SYBR Green and 300nM of 
specific primers. After an initial denaturation at 95 ºC for 
5min, 35 cycles were carried out as follows: denaturation 
at 95 ºC for 30s, annealing temperature for 30s and 
polymerization at 72 ºC for 20s. The amplified PCR 
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fragments were analyzed by melting curves: reactions 
were heated from 55 to 95ºC with 10s holds at each 
temperature (0.05ºC/s). Fold differences were calculated 
following the mathematical model proposed by Pfaffl [26]. 
Western blot
Approximately 80µg of total protein from PNT1A, 
PNT2, PC3 and LNCaP cells were used to assess the 
STEAP1 protein expression on the four cell lines, and 
to determine protein stability. The protocol followed as 
previously been described by us [27]. Briefly, LNCaP and 
PNT1A protein extracts were resolved on 12% SDS-PAGE 
electrophoresis gel and then transferred into a PVDF 
membrane (GE Healthecare, UK). After blockage with 3% 
casein solution, membranes were incubated with STEAP1 
rabbit polyclonal antibody against humanSTEAP1 
(H105) diluted 1:300 (Santa Cruz Biotechnology, Santa 
Cruz). Membranes were then incubated with an alkaline 
phosphatase conjugated goat polyclonal antibody against 
rabbit IgG (GE Healthcare, UK). Finally, STEAP1 
immunoreactivity was visualized using Molecular Imager 
FX (Biorad, Hercules) after a brief incubation with ECF 
substract. STEAP1 and β-actin expression levels were 
quantified by densitometry using Quantity One Software 
(Biorad). β-actin was used to normalize STEAP1 
expression.
Bioinformatic analysis
mRNA and protein sequences of STEAP1, 
STEAP1B1 and STEAP1B2 were retrieved from the 
National Center for Biotechnology Information (http://
www.ncbi.nlm.nih.gov/). . Alignment of amino acid 
(aa) sequences was performed using Clustal Omega 
program (https://www.ebi.ac.uk/Tools/msa/clustalo/). 
To determine protein homology, the online Basic Local 
Alignment Search Tool program (BLAST) (http://blast.
ncbi.nlm.nih.gov/Blast.cgi) was used. Prediction of 
putative transmembranar domains was determined using 
TMHMM Server v. 2.0 (http://www.cbs.dtu.dk/services/
TMHMM). Prediction of amino acid post-translational 
alterations such as N-glycosylation, N-Glycation, 
Phosphorylation and Phosphokinase specific sites, and 
addition sites of O-linked β-N-acetylglucosamine (O-β-
GlcNAc) were carried out using several tools available 
on Expasy ((http://www.expasy.org/proteomics/post-
translational_modification), NetNGlyc 1.0, NetGlycate 1.0 
[28], NetPhos 2.0 [29], NetPhosK 1.0 [30] and YinOYang 
1.2 [31] software’s, respectively.
Statistical analysis
Data from all experiences are shown as mean ± 
SEM of n=6. The statistical significance of STEAP1, 
STEAP1B1 and STEAP1B2 was assessed using One-
way ANOVA followed by Bonferroni test. mRNA and 
protein stability experiments statistical data was obtained 
comparing PNT1A and LNCaP STEAP1 expression at 
each indicated time, using t-test. 
FINANCIAL SUPPORT 
This work was partially supported by the COMPETE 
program (Pest-C/SAU/UI0709/2011) of Portuguese 
Foundation for Science and Technology (FCT).
REFERENCES
1. Grunewald TG, Diebold I, Esposito I, Plehm S, Hauer K, 
Thiel U, da Silva-Buttkus P, Neff F, Unland R, Muller-
Tidow C, Zobywalski C, Lohrig K, Lewandrowski U, 
Sickmann A, Prazeres da Costa O, Gorlach A, et al. 
STEAP1 is associated with the invasive and oxidative 
stress phenotype of Ewing tumors. Mol Cancer Res. 2012; 
10(1):52-65.
2. Hubert RS, Vivanco I, Chen E, Rastegar S, Leong K, 
Mitchell SC, Madraswala R, Zhou Y, Kuo J, Raitano 
AB, Jakobovits A, Saffran DC and Afar DEH. STEAP: a 
prostate-specific cell-surface antigen highly expressed in 
human prostate tumors. Proc Natl Acad Sci U S A. 1999; 
96(25):14523-14528.
3. Maia CJB, Socorro S, Schmitt F and Santos CR. STEAP1 
is over-expressed in breast cancer and down-regulated by 
17beta-estradiol in MCF-7 cells and in the rat mammary 
gland. Endocrine. 2008; 34(1-3):108-116.
4. Yang D, Holt GE, Velders MP, Kwon ED and Kast WM. 
Murine six-transmembrane epithelial antigen of the prostate, 
prostate stem cell antigen, and prostate-specific membrane 
antigen: prostate-specific cell-surface antigens highly 
expressed in prostate cancer of transgenic adenocarcinoma 
mouse prostate mice. Cancer Res. 2001; 61(15):5857-5860.
5. Gomes IM, Santos CR, Socorro S and Maia CJ. Six 
transmembrane epithelial antigen of the prostate 1 is down-
regulated by sex hormones in prostate cells. The Prostate. 
2012; 73(6):605-613.
6. Challita-Eid PM, Morrison K, Etessami S, An Z, Morrison 
KJ, Perez-Villar JJ, Raitano AB, Jia X-C, Gudas JM, 
Kanner SB and Jakobovits A. Monoclonal antibodies to six-
transmembrane epithelial antigen of the prostate-1 inhibit 
intercellular communication in vitro and growth of human 
tumor xenografts in vivo. Cancer Res. 2007; 67(12):5798-
5805.
7. Alves PMS, Faure O, Graff-Dubois S, Cornet S, Bolonakis 
I, Gross D-A, Miconnet I, Chouaib S, Fizazi K, Soria JC, 
Genes & Cancer150www.impactjournals.com/Genes & Cancer
Lemonnier FA and Kosmatopoulos K. STEAP, a prostate 
tumor antigen, is a target of human CD8+ T cells. Cancer 
Immunol Immunother. 2006; 55(12):1515-1523.
8. Azumi M, Kobayashi H, Aoki N, Sato K, Kimura S, 
Kakizaki H and Tateno M. Six-transmembrane epithelial 
antigen of the prostate as an immunotherapeutic target for 
renal cell and bladder cancer. J Urol. 2010; 183(5):2036-
2044.
9. Garcia-Hernandez MDLL, Gray A, Hubby B and Kast 
WM. In vivo effects of vaccination with six-transmembrane 
epithelial antigen of the prostate: a candidate antigen for 
treating prostate cancer. Cancer Res. 2007; 67(3):1344-
1351.
10. Grunewald T, Ranft A, Esposito I, da Silva-Buttkus P, 
Aichler M, Baumhoer D, Schaefer K, Ottaviano L, Poremba 
C and Jundt G. High STEAP1 expression is associated 
with improved outcome of Ewing’s sarcoma patients. Ann 
Oncol. 2012; 23(8):2185-2190.
11. Valenti MT, Dalle Carbonare L, Donatelli L, Bertoldo F, 
Giovanazzi B, Caliari F and Lo Cascio V. STEAP mRNA 
detection in serum of patients with solid tumours. Cancer 
Lett. 2009; 273(1):122-126.
12. Kirkpatrick DS, Denison C and Gygi SP. Weighing in on 
ubiquitin: the expanding role of mass-spectrometry-based 
proteomics. Nature cell biology. 2005; 7(8):750-757.
13. Hershko A and Ciechanover A. The ubiquitin system. Annu 
Rev Biochem. 1998; 67:425-479.
14. King RW, Deshaies RJ, Peters JM and Kirschner MW. 
How proteolysis drives the cell cycle. Science. 1996; 
274(5293):1652-1659.
15. Hao S and Baltimore D. The stability of mRNA influences 
the temporal order of the induction of genes encoding 
inflammatory molecules. Nature immunology. 2009; 
10(3):281-288.
16. Friedel CC, Dolken L, Ruzsics Z, Koszinowski UH 
and Zimmer R. Conserved principles of mammalian 
transcriptional regulation revealed by RNA half-life. 
Nucleic Acids Res. 2009; 37(17):e115.
17. Hollams EM, Giles KM, Thomson AM and Leedman 
PJ. mRNA stability and the control of gene expression: 
implications for human disease. Neurochemical research. 
2002; 27(10):957-980.
18. Aghib DF, Bishop JM, Ottolenghi S, Guerrasio A, Serra 
A and Saglio G. A 3’ truncation of MYC caused by 
chromosomal translocation in a human T-cell leukemia 
increases mRNA stability. Oncogene. 1990; 5(5):707-711.
19. Hollis GF, Gazdar AF, Bertness V and Kirsch IR. Complex 
translocation disrupts c-myc regulation in a human plasma 
cell myeloma. Mol Cell Biol. 1988; 8(1):124-129.
20. Jones TR and Cole MD. Rapid cytoplasmic turnover 
of c-myc mRNA: requirement of the 3’ untranslated 
sequences. Mol Cell Biol. 1987; 7(12):4513-4521.
21. Lasa M, Mahtani KR, Finch A, Brewer G, Saklatvala J and 
Clark AR. Regulation of cyclooxygenase 2 mRNA stability 
by the mitogen-activated protein kinase p38 signaling 
cascade. Mol Cell Biol. 2000; 20(12):4265-4274.
22. Ross HJ, Sato N, Ueyama Y and Koeffler HP. Cytokine 
messenger RNA stability is enhanced in tumor cells. Blood. 
1991; 77(8):1787-1795.
23. Schuler GD and Cole MD. GM-CSF and oncogene mRNA 
stabilities are independently regulated in trans in a mouse 
monocytic tumor. Cell. 1988; 55(6):1115-1122.
24. Seet BT, Dikic I, Zhou MM and Pawson T. Reading protein 
modifications with interaction domains. Nat Rev Mol Cell 
Bio. 2006; 7(7):473-483.
25. Yang XJ. Multisite protein modification and intramolecular 
signaling. Oncogene. 2005; 24(10):1653-1662.
26. Pfaffl MW. A new mathematical model for relative 
quantification in real-time RT-PCR. Nucleic Acids Res. 
2001; 29(9):e45.
27. Gomes IM, Santos CR, Socorro S and Maia CJ. Six 
transmembrane epithelial antigen of the prostate 1 is down-
regulated by sex hormones in prostate cells. Prostate. 2012.
28. Johansen MB, Kiemer L and Brunak S. Analysis and 
prediction of mammalian protein glycation. Glycobiology. 
2006; 16(9):844-853.
29. Blom N, Gammeltoft S and Brunak S. Sequence 
and structure-based prediction of eukaryotic protein 
phosphorylation sites. J Mol Biol. 1999; 294(5):1351-1362.
30. Blom N, Sicheritz-Ponten T, Gupta R, Gammeltoft S and 
Brunak S. Prediction of post-translational glycosylation and 
phosphorylation of proteins from the amino acid sequence. 
Proteomics. 2004; 4(6):1633-1649.
31. Gupta R and Brunak S. Prediction of glycosylation across 
the human proteome and the correlation to protein function. 
Pacific Symposium on Biocomputing Pacific Symposium 
on Biocomputing. 2002:310-322.
32. Schwarz F and Aebi M. Mechanisms and principles of 
N-linked protein glycosylation. Current opinion in structural 
biology. 2011; 21(5):576-582.
33. Wang Z, Pandey A and Hart GW. Dynamic interplay 
between O-linked N-acetylglucosaminylation and glycogen 
synthase kinase-3-dependent phosphorylation. Molecular & 
Cellular Proteomics. 2007; 6(8):1365-1379.
34. Wang Z, Gucek M and Hart GW. Cross-talk between 
GlcNAcylation and phosphorylation: site-specific 
phosphorylation dynamics in response to globally elevated 
O-GlcNAc. Proceedings of the National Academy of 
Sciences. 2008; 105(37):13793-13798.
35. Grunewald TG, Bach H, Cossarizza A and Matsumoto I. 
The STEAP protein family: versatile oxidoreductases and 
targets for cancer immunotherapy with overlapping and 
distinct cellular functions. Biol Cell. 2012; 104(11):641-
657.
36. Ohgami RS, Campagna DR, McDonald A and Fleming 
MD. The Steap proteins are metalloreductases. Blood. 
2006; 108(4):1388-1394.
37. Finegold AA, Shatwell KP, Segal AW, Klausner RD 
Genes & Cancer151www.impactjournals.com/Genes & Cancer
and Dancis A. Intramembrane bis-heme motif for 
transmembrane electron transport conserved in a yeast iron 
reductase and the human NADPH oxidase. J Biol Chem. 
1996; 271(49):31021-31024.
38. Ohgami RS, Campagna DR, Greer EL, Antiochos B, 
Mcdonald A, Chen J, Sharp JJ, Fujiwara Y, Barker JE and 
Fleming MD. Identification of a ferrireductase required 
for efficient transferrin-dependent iron uptake in erythroid 
cells. Nat Genet. 2005; 37(11):1264-1269.
39. Sanchez-Pulido L, Rojas AM, Valencia A, Martinez-A 
C and Andrade Ma. ACRATA: a novel electron transfer 
domain associated to apoptosis and cancer. BMC Cancer. 
2004; 4:98.
40. Guhaniyogi J and Brewer G. Regulation of mRNA stability 
in mammalian cells. Gene. 2001; 265(1-2):11-23.
41. Ross J. mRNA stability in mammalian cells. 
Microbiological reviews. 1995; 59(3):423-450.
42. Wagner A. Energy constraints on the evolution of gene 
expression. Mol Biol Evol. 2005; 22(6):1365-1374.
43. Yeap BB, Krueger RG and Leedman PJ. Differential 
posttranscriptional regulation of androgen receptor gene 
expression by androgen in prostate and breast cancer cells. 
Endocrinology. 1999; 140(7):3282-3291.
44. Russell JE, Morales J and Liebhaber SA. The role of mRNA 
stability in the control of globin gene expression. Prog 
Nucleic Acid Re. 1997; 57:249-287.
45. Hanson SR, Culyba EK, Hsu TL, Wong CH, Kelly JW 
and Powers ET. The core trisaccharide of an N-linked 
glycoprotein intrinsically accelerates folding and enhances 
stability. Proc Natl Acad Sci U S A. 2009; 106(9):3131-
3136.
46. Shental-Bechor D and Levy Y. Effect of glycosylation on 
protein folding: a close look at thermodynamic stabilization. 
Proc Natl Acad Sci U S A. 2008; 105(24):8256-8261.
47. Ling X, Sakashita N, Takeya M, Nagai R, Horiuchi S 
and Takahashi K. Immunohistochemical distribution and 
subcellular localization of three distinct specific molecular 
structures of advanced glycation end products in human 
tissues. Lab Invest. 1998; 78(12):1591-1606.
48. Yang WH, Kim JE, Nam HW, Ju JW, Kim HS, Kim 
YS and Cho JW. Modification of p53 with O-linked 
N-acetylglucosamine regulates p53 activity and stability. 
Nature cell biology. 2006; 8(10):1074-1083.
49. Lynch TP, Ferrer CM, Jackson SR, Shahriari KS, 
Vosseller K and Reginato MJ. Critical role of O-Linked 
beta-N-acetylglucosamine transferase in prostate cancer 
invasion, angiogenesis, and metastasis. J Biol Chem. 2012; 
287(14):11070-11081.
50. Chu C-S, Lo P-W, Yeh Y-H, Hsu P-H, Peng S-H, Teng Y-C, 
Kang M-L, Wong C-H and Juan L-J. O-GlcNAcylation 
regulates EZH2 protein stability and function. Proceedings 
of the National Academy of Sciences. 2014; 111(4):1355-
1360.
51. Yoon SJ, Park SY, Pang PC, Gallagher J, Gottesman JE, 
Dell A, Kim JH and Hakomori SI. N-glycosylation status of 
beta-haptoglobin in sera of patients with prostate cancer vs. 
benign prostate diseases. Int J Oncol. 2010; 36(1):193-203.
52. Fujimura T, Shinohara Y, Tissot B, Pang PC, Kurogochi 
M, Saito S, Arai Y, Sadilek M, Murayama K, Dell A, 
Nishimura S and Hakomori SI. Glycosylation status of 
haptoglobin in sera of patients with prostate cancer vs. 
benign prostate disease or normal subjects. Int J Cancer. 
2008; 122(1):39-49.
53. Kamigaito T, Okaneya T, Kawakubo M, Shimojo H, 
Nishizawa O and Nakayama J. Overexpression of 
O-GlcNAc by prostate cancer cells is significantly 
associated with poor prognosis of patients. Prostate Cancer 
Prostatic Dis. 2014; 17(1):18-22.
